IDEXX Laboratories Aktie 940695 / US45168D1046
417.04
USD
8.25
USD
2.02%
18:00:32
BTT
| Kurse + Charts + Realtime | News + Analysen | Fundamental | Unternehmen | zugeh. Wertpapiere | Aktion | |
|---|---|---|---|---|---|---|
| Kurs + Chart | Chart (gross) | News + Adhoc | Bilanz/GuV | Termine | Strukturierte Produkte | Portfolio |
| Times + Sales | Chartvergleich | Analysen | Schätzungen | Profil | Watchlist | |
| Börsenplätze | Realtime Push | Kursziele | Dividende/GV | |||
| Historisch | Analysen | |||||
Kurse + Charts + Realtime
News + Analysen
Fundamental
zugeh. Wertpapiere
IDEXX Laboratories Dividenden Kalender
| Datum | Name | Rendite * | Dividende | Währung |
|---|---|---|---|---|
| 2023 | IDEXX Laboratories | 0.00 | 0.00 | USD |
| 2022 | IDEXX Laboratories | 0.00 | 0.00 | USD |
| 2021 | IDEXX Laboratories | 0.00 | 0.00 | USD |
| 2020 | IDEXX Laboratories | 0.00 | 0.00 | USD |
| 2019 | IDEXX Laboratories | 0.00 | 0.00 | USD |
| 2018 | IDEXX Laboratories | 0.00 | 0.00 | USD |
| 2017 | IDEXX Laboratories | 0.00 | 0.00 | USD |
| 2016 | IDEXX Laboratories | 0.00 | 0.00 | USD |
| 2015 | IDEXX Laboratories | 0.00 | 0.00 | USD |
| 2014 | IDEXX Laboratories | 0.00 | 0.00 | USD |
Gewinn je Aktie- IDEXX Laboratories
| 10.1 23 | 8.0 22 | 8.6 21 | 6.7 20 | 4.9 19 | 4.3 18 | 2.9 17 |
Umsatz je Aktie- IDEXX Laboratories
| 43.6 23 | 39.8 22 | 37.1 21 | 31.2 20 | 27.5 19 | 25.0 18 | 22.0 17 |
KGV- IDEXX Laboratories
| 55.2 23 | 50.8 22 | 76.5 21 | 74.5 20 | 53.4 19 | 43.7 18 | 53.2 17 |
IDEXX Laboratories: Die Aktie (in USD)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|
| Gewinn je Aktie berichtet | 10.06 | 8.03 | 8.60 | 6.71 | 4.89 | 4.26 | 2.94 |
| Gewinn je Aktie unverwässert | 10.17 | 8.12 | 8.74 | 6.82 | 4.97 | 4.34 | 3.00 |
| Gewinn je Aktie verwässert | 10.06 | 8.03 | 8.60 | 6.71 | 4.89 | 4.26 | 2.94 |
| Dividende pro Aktie | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gesamtdividendenausschüttung in Mio. | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
IDEXX Laboratories: Unternehmenskennzahlen (in USD)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|
| Umsatz je Aktie | 43.59 | 39.80 | 37.14 | 31.21 | 27.49 | 25.02 | 21.98 |
| KGV (Jahresendkurs, EPS unverwässert) | 55.16 | 50.82 | 76.53 | 74.51 | 53.45 | 43.67 | 53.19 |
| KGV (Jahresendkurs, EPS verwässert) | 55.16 | 50.82 | 76.53 | 74.51 | 53.45 | 43.67 | 53.19 |
| KGV (Jahresendkurs) | 55.16 | 50.82 | 76.53 | 74.51 | 53.45 | 43.67 | 53.19 |
| Dividendenrendite Jahresende in % | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Eigenkapitalquote in % | 45.54 | 22.16 | 28.31 | 27.58 | 9.70 | -0.60 | -3.14 |
| Fremdkapitalquote in % | 54.46 | 77.84 | 71.69 | 72.42 | 90.30 | 100.60 | 103.14 |
IDEXX Laboratories: GuV (in Mio. USD)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|
| Umsatzerlöse | 3’660.95 | 3’367.32 | 3’215.36 | 2’706.66 | 2’406.91 | 2’213.24 | 1’969.06 |
| Umsatzveränderung in % | 8.72 | 4.73 | 18.79 | 12.45 | 8.75 | 12.40 | 10.91 |
| Bruttoergebnis vom Umsatz | 2’186.46 | 1’978.61 | 1’901.65 | 1’570.21 | 1’354.92 | 1’242.52 | 1’097.36 |
| Bruttoergebnisveränderung in % | 10.51 | 4.05 | 21.11 | 15.89 | 9.05 | 13.23 | 12.92 |
| Operatives Ergebnis | 1’092.52 | 876.43 | 948.35 | 696.20 | 543.19 | 494.94 | 413.00 |
| Veränderung Operatives Ergebnis in % | 24.65 | -7.58 | 36.22 | 28.17 | 9.75 | 19.84 | 19.15 |
| Ergebnis vor Steuern | 1’061.18 | 859.97 | 902.65 | 661.99 | 522.22 | 457.74 | 381.06 |
| Veränderung Ergebnis vor Steuern in % | 23.40 | -4.73 | 36.36 | 26.76 | 14.09 | 20.12 | 18.40 |
| Ergebnis nach Steuer | 845.04 | 679.09 | 744.85 | 581.78 | 427.72 | 377.03 | 263.14 |
| Veränderung Ergebnis nach Steuer in % | 24.44 | -8.83 | 28.03 | 36.02 | 13.44 | 43.28 | 18.51 |
IDEXX Laboratories: Bilanz (in Mio. USD)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|
| Gesamtverbindlichkeiten | 1’775 | 2’138 | 1’747 | 1’662 | 1’655 | 1’547 | 1’767 |
| Langzeit Gesamtverbindlichk. pro Aktie | 9.92 | 10.88 | 11.63 | 12.61 | 10.85 | 9.00 | 8.73 |
| Eigenkapital | 1’485 | 609 | 690 | 633 | 178 | -9 | -54 |
| Veränderung Eigenkapital in % | 143.87 | -11.78 | 9.16 | 256.16 | - | 82.42 | 50.06 |
| Bilanzsumme | 3’260 | 2’747 | 2’437 | 2’295 | 1’832 | 1’537 | 1’713 |
| Veränderung Bilanzsumme in % | 18.68 | 12.70 | 6.22 | 25.22 | 19.20 | -10.28 | 11.94 |
IDEXX Laboratories: Sonstige Angaben (in USD)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|
| Gewinn je Aktie (unverwässert) | 10.17 | 8.12 | 8.74 | 6.82 | 4.97 | 4.34 | 3.00 |
| Veränderung Gewinn je Aktie (unverwässert) in % | 25.27 | -7.11 | 28.24 | 37.25 | 14.44 | 44.67 | 21.46 |
| Gewinn je Aktie (verwässert) | 10.06 | 8.03 | 8.60 | 6.71 | 4.89 | 4.26 | 2.94 |
| Veränderung Gewinn je Aktie (verwässert) in % | 25.36 | -6.70 | 28.25 | 37.30 | 14.69 | 44.90 | 20.49 |
| Anzahl Mitarbeiter | 11’000 | 10’780 | 10’350 | 9’300 | 9’200 | 8’377 | 7’600 |
| Veränderung Anzahl Mitarbeiter in % | 2.04 | 4.15 | 11.29 | 1.09 | 9.82 | 10.22 | 3.19 |
IDEXX Laboratories Termine
| Unternehmen | Event | Datum |
|---|---|---|
| IDEXX Laboratories | Quartalszahlen | 10.02.2025 |
| IDEXX Laboratories | Quartalszahlen | 30.04.2025 |
| IDEXX Laboratories | Quartalszahlen | 05.08.2025 |
| IDEXX Laboratories | Quartalszahlen | 04.11.2025 |
IDEXX Laboratories vergangene Termine
| Terminart | Info | Datum |
|---|---|---|
| Quartalszahlen | Q3 2024 Earnings Release | 31.10.2024 |
| Quartalszahlen | Q2 2024 Earnings Release | 06.08.2024 |
| Hauptversammlung | Annual General Meeting | 06.05.2024 |
| Quartalszahlen | Q1 2024 Earnings Release | 01.05.2024 |
| Quartalszahlen | Q4 2023 Earnings Release | 05.02.2024 |
| Quartalszahlen | Q3 2023 Earnings Release | 01.11.2023 |
| Quartalszahlen | Q2 2023 Earnings Release | 01.08.2023 |
| Hauptversammlung | Annual General Meeting | 17.05.2023 |
| Quartalszahlen | Q1 2023 Earnings Release | 02.05.2023 |
| Quartalszahlen | Q4 2022 Earnings Release | 06.02.2023 |
| Quartalszahlen | Q3 2022 Earnings Release | 01.11.2022 |
| Quartalszahlen | Q2 2022 Earnings Release | 02.08.2022 |
| Hauptversammlung | Annual General Meeting | 11.05.2022 |
| Quartalszahlen | Q1 2022 Earnings Release | 04.05.2022 |
| Quartalszahlen | Q4 2021 Earnings Release | 02.02.2022 |
Aktionärsstruktur
| Inhaber | in % |
|---|---|
| Freefloat | 99.01 |
| The Vanguard Group, Inc. | 11.85 |
| Vanguard Group, Inc. (Subfiler) | 11.39 |
| State Street Corp. | 4.41 |
| BlackRock Fund Advisors | 4.38 |
| AllianceBernstein LP | 3.44 |
| Fundsmith LLP | 3.25 |
| Vanguard Total Stock Market ETF | 3.17 |
| Fundsmith Equity Fund | 3.08 |
| Geode Capital Management LLC | 2.76 |
| Vanguard 500 Index Fund | 2.66 |
| BlackRock Institutional Trust Co. NA | 2.41 |
| BAMCO, Inc. | 2.35 |
| Vanguard Mid Cap Index Fund | 2.13 |
| Invesco QQQ Trust | 2.00 |
*Die Summe der Anteile kann 100% überschreiten, da bestimmte Anteilseigner zum Freefloat dazu gerechnet wurden.
Personal
| 2017 | 2018 | 2019 | 2020 | 2021 | |
|---|---|---|---|---|---|
| Personal am Ende des Jahres | 7’600 | 8’377 | 9’200 | 9’300 | 10’350 |
| Umsatz pro Mitarbeiter in Mio. EUR | 0.26 | 0.26 | 0.26 | 0.29 | 0.31 |
Bilanz (in Mio. USD) - Aktiva
| 2017 | 2018 | 2019 | 2020 | 2021 | |
|---|---|---|---|---|---|
| Summe Umlaufvermögen | 948 | 615 | 635 | 1’013 | 900 |
| Summe Anlagevermögen | 765 | 922 | 1’197 | 1’281 | 1’537 |
| Summe Aktiva | 1’713 | 1’537 | 1’832 | 2’295 | 2’437 |
Bilanz (in Mio. USD) - Passiva
| 2017 | 2018 | 2019 | 2020 | 2021 | |
|---|---|---|---|---|---|
| Summe Fremdkapital | 1’767 | 1’547 | 1’655 | 1’662 | 1’747 |
| Summe Eigenkapital | -54 | -9 | 178 | 633 | 690 |
| Summe Passiva | 1’713 | 1’537 | 1’832 | 2’295 | 2’437 |
Adresse
| One IDEXX Drive, 04092-2040 Westbrook | |
| Telefon | +1 (207) 556-0300 |
| Fax | +1 (207) 556-4346 |
| URL | http://www.idexx.com |
Management
|
Andrew Emerson
Senior Vice President-Corporate |
|
Asha S. Collins
Independent Director |
|
Brian Patrick McKeon
Chief Financial Officer, Treasurer & Executive VP |
|
Bruce L. Claflin
Independent Director |
|
Daniel M. Junius
Independent Director |
|
George J. Fennell
Chief Revenue Officer & Senior Vice President |
|
Irene Chang Britt
Independent Director |
|
Jeffery Donn Chadbourne
SVP-Commercial Finance & Sales Operations |
|
John Hart
Senior Vice President-Global Operations |
|
John Ravis
Investor Relations Contact |
|
Jonathan J. Mazelsky
President, Chief Executive Officer & Director |
|
Ken Grady
Chief Information Officer & Senior VP |
|
Kerry Bennett
SVP, GM-Product, Strategy & Global Reference Labs |
|
Lawrence D. Kingsley
Non-Executive Chairman |
|
M. Anne Szostak
Independent Director |
|
Martin Alexander Smith
Chief Technology Officer & Executive VP |
|
Michael Erickson
EVP & GM-Point of Care Diagnostics & Telemedicine |
|
Michael J. Lane
Executive VP, GM-Reference Laboratories & IT |
|
Michael P. Johnson
Chief Human Resources Officer & Executive VP |
|
Michael Schreck
EVP, GM-Corporate Accounts & Customer Experience |
|
Murthy Yerramilli
Senior Vice President-Research & Development |
|
Sam A. Samad
Independent Director |
|
Sharon E. Underberg
Secretary, Executive VP & General Counsel |
|
Sophie V. Vandebroek
Independent Non-Executive Director |
|
Stuart M. Essig
Independent Director |
|
Tina Hunt
Executive Vice President-Strategy |